Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease
Background. Exhaled nitric oxide (eNO) is a potential biomarker to distinguish systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). We evaluated the discriminative validity, feasibility, methods of eNO measurement, and magnitude of difference...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2017/6736239 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558932810268672 |
|---|---|
| author | Natalie K. Kozij John T. Granton Philip E. Silkoff John Thenganatt Shobha Chakravorty Sindhu R. Johnson |
| author_facet | Natalie K. Kozij John T. Granton Philip E. Silkoff John Thenganatt Shobha Chakravorty Sindhu R. Johnson |
| author_sort | Natalie K. Kozij |
| collection | DOAJ |
| description | Background. Exhaled nitric oxide (eNO) is a potential biomarker to distinguish systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). We evaluated the discriminative validity, feasibility, methods of eNO measurement, and magnitude of differences across lung diseases, disease-subsets (SSc, systemic lupus erythematosus), and healthy-controls. Methods. Consecutive subjects in the UHN Pulmonary Hypertension Programme were recruited. Exhaled nitric oxide was measured at 50 mL/s intervals using chemiluminescent detection. Alveolar and conducting airway NO were partitioned using a two-compartment model of axial diffusion (CMAD) and the trumpet model of axial diffusion (TMAD). Results. Sixty subjects were evaluated. Using the CMAD model, control subjects had lower median (IQR) alveolar NO than all PAH subjects (2.0 (1.5, 2.5) versus 3.14 ppb (2.3, 4.0), p=0.008). SSc-ILD had significantly lower median conducting airway NO compared to controls (1009.5 versus 1342.1 ml⁎ppb/s, p=0.04). SSc-PAH had increased median (IQR) alveolar NO compared to controls (3.3 (3.0, 5.7) versus 2.0 ppb (1.5, 2.5), p=0.01). SSc-PAH conducting airway NO inversely correlated with DLCO (r −0.88 (95% CI −0.99, −0.26)). Conclusion. We have demonstrated feasibility, identified that CMAD modeling is preferred in SSc, and reported the magnitude of differences across cases and controls. Our data supports discriminative validity of eNO in SSc lung disease. |
| format | Article |
| id | doaj-art-5d63911214d84f1dbea3fa914a87a204 |
| institution | Kabale University |
| issn | 1198-2241 1916-7245 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-5d63911214d84f1dbea3fa914a87a2042025-02-03T01:31:17ZengWileyCanadian Respiratory Journal1198-22411916-72452017-01-01201710.1155/2017/67362396736239Exhaled Nitric Oxide in Systemic Sclerosis Lung DiseaseNatalie K. Kozij0John T. Granton1Philip E. Silkoff2John Thenganatt3Shobha Chakravorty4Sindhu R. Johnson5University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Department of Medicine, University of Toronto, Toronto, ON, CanadaUniversity Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Department of Medicine, University of Toronto, Toronto, ON, CanadaDepartment of Medicine, Temple University, Philadelphia, PA, USAUniversity Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Department of Medicine, University of Toronto, Toronto, ON, CanadaUniversity Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Toronto, ON, CanadaUniversity Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, Department of Medicine, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, CanadaBackground. Exhaled nitric oxide (eNO) is a potential biomarker to distinguish systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). We evaluated the discriminative validity, feasibility, methods of eNO measurement, and magnitude of differences across lung diseases, disease-subsets (SSc, systemic lupus erythematosus), and healthy-controls. Methods. Consecutive subjects in the UHN Pulmonary Hypertension Programme were recruited. Exhaled nitric oxide was measured at 50 mL/s intervals using chemiluminescent detection. Alveolar and conducting airway NO were partitioned using a two-compartment model of axial diffusion (CMAD) and the trumpet model of axial diffusion (TMAD). Results. Sixty subjects were evaluated. Using the CMAD model, control subjects had lower median (IQR) alveolar NO than all PAH subjects (2.0 (1.5, 2.5) versus 3.14 ppb (2.3, 4.0), p=0.008). SSc-ILD had significantly lower median conducting airway NO compared to controls (1009.5 versus 1342.1 ml⁎ppb/s, p=0.04). SSc-PAH had increased median (IQR) alveolar NO compared to controls (3.3 (3.0, 5.7) versus 2.0 ppb (1.5, 2.5), p=0.01). SSc-PAH conducting airway NO inversely correlated with DLCO (r −0.88 (95% CI −0.99, −0.26)). Conclusion. We have demonstrated feasibility, identified that CMAD modeling is preferred in SSc, and reported the magnitude of differences across cases and controls. Our data supports discriminative validity of eNO in SSc lung disease.http://dx.doi.org/10.1155/2017/6736239 |
| spellingShingle | Natalie K. Kozij John T. Granton Philip E. Silkoff John Thenganatt Shobha Chakravorty Sindhu R. Johnson Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease Canadian Respiratory Journal |
| title | Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease |
| title_full | Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease |
| title_fullStr | Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease |
| title_full_unstemmed | Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease |
| title_short | Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease |
| title_sort | exhaled nitric oxide in systemic sclerosis lung disease |
| url | http://dx.doi.org/10.1155/2017/6736239 |
| work_keys_str_mv | AT nataliekkozij exhalednitricoxideinsystemicsclerosislungdisease AT johntgranton exhalednitricoxideinsystemicsclerosislungdisease AT philipesilkoff exhalednitricoxideinsystemicsclerosislungdisease AT johnthenganatt exhalednitricoxideinsystemicsclerosislungdisease AT shobhachakravorty exhalednitricoxideinsystemicsclerosislungdisease AT sindhurjohnson exhalednitricoxideinsystemicsclerosislungdisease |